Sunshine Heart, Inc. — FY 2016 Form 10-K
Period and identity: This is an annual report for the fiscal year ended December 31, 2016, not a standalone fourth-quarter report. The filing names the registrant as Sunshine Heart, Inc.; the request metadata names Nuwellis, Inc. Financial figures below are for Sunshine Heart and its subsidiaries. Per-share and share amounts were retroactively adjusted for a 1-for-30 reverse split effective January 12, 2017.
Business context
The company shifted from developing the C-Pulse heart-assist system to commercializing the Aquadex FlexFlow ultrafiltration system, acquired from Baxter on August 5, 2016. In September, it halted clinical evaluations of its neuromodulation technology and refocused resources on Aquadex. The device is indicated for treating fluid-overloaded patients who have failed diuretic therapy. The company reported more than 500 installed consoles in U.S. hospitals, with revenue primarily from disposable blood sets and catheters.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Net sales | $1.289 million | $59,000 |
| Cost of goods sold | $713,000 | — |
| Gross profit / margin | $576,000 / approximately 44.7% | Not meaningful for comparison |
| Operating expenses | $16.951 million | $26.017 million |
| Loss from operations | $15.662 million | $25.958 million |
| Net loss | $15.792 million | $26.583 million |
| Basic and diluted loss per share | $27.06 | $44.01 |
| Net cash used in operating activities | $16.292 million | $22.989 million |
| Cash and cash equivalents at year-end | $1.323 million | $23.113 million |
- FY 2016 sales included $1.23 million from Aquadex after the acquisition and $59,000 from a C-Pulse clinical-study implant. The company had no commercial sales before acquiring Aquadex.
- Research and development expense fell 54.1% to $8.109 million, mainly after C-Pulse enrollment ended and neuromodulation evaluations were halted. Selling, general and administrative expense declined 2.6% to $8.129 million despite $1.1 million of incremental Aquadex commercialization expenses and $0.9 million of acquisition transaction fees.
- Investing cash use was $4.117 million, including $4.0 million for the Aquadex acquisition. Financing cash use was $1.364 million, reflecting debt repayment partly offset by preferred-stock proceeds.
- At December 31, 2016, current assets were $2.419 million and current liabilities were $3.260 million, implying negative working capital of approximately $841,000. Total assets were $7.471 million, total liabilities $5.229 million, and reported stockholders’ equity $1.757 million; Series D preferred stock of $485,000 was presented as temporary equity.
- No borrowings were outstanding at year-end. The prior $5.5 million Silicon Valley Bank balance was repaid in August 2016; a new facility included an unused term loan and a revolving line of credit with no year-end borrowings.
Changes, outlook, and material items
- The reduction in annual net loss chiefly reflected lower R&D spending. Results also included an $818,000 gain from a decline in the fair value of warrant liabilities and a $500,000 loss on early debt retirement. The warrant gain is a fair-value item, not operating revenue.
- Management expected Aquadex revenue to grow in coming quarters as it sought to increase disposable utilization across the installed base. It planned to prioritize major existing hospital accounts, expand customer re-engagement, and build sales, clinical education, and service capabilities. No quantified revenue, earnings, or cash-flow guidance was provided.
- The company expected ongoing near-term losses and said cash on hand and warrant-exercise proceeds were expected to fund operations until mid-2017. It expected to seek additional financing during 2017; the filing cautions that funding might not be available on acceptable terms or at all. A February 2017 warrant agreement had already generated approximately $564,000 in gross proceeds and could generate approximately $4.65 million if eligible warrants were exercised in full, in exchange for replacement warrants.
- The independent auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern. The financial statements were prepared on a going-concern basis without adjustments that might be required if the company could not continue operating.
- Manufacturing transition was a key execution risk: Baxter was to supply blood sets and catheters for up to 18 months after the acquisition; the company planned to transition console manufacturing by mid-2017 and disposable manufacturing by year-end 2017. On termination of the supply agreement, it could have to purchase remaining inventory, estimated at no more than $2.5 million.
- Reimbursement remained uncertain: CMS had not issued favorable national coverage for Aquadex ultrafiltration, although some private insurers covered specified uses. Clinical evidence was mixed: UNLOAD showed greater fluid and weight loss and fewer heart-failure rehospitalizations; CARESS found no weight-loss difference and a creatinine increase; AVOID ended early and was underpowered.
- Nasdaq had granted continued listing while the company worked to meet bid-price and stockholders’ equity requirements. Following the reverse split, it regained minimum-bid-price compliance in February 2017, but the $2.5 million equity requirement remained subject to a March 20, 2017 deadline.
Important facts for investors to verify
- Whether post-acquisition Aquadex sales and utilization grew enough to reduce cash burn, and how much revenue is recurring disposable sales.
- Actual cash runway and subsequent financing: distinguish warrant proceeds already received from potential proceeds dependent on further exercises, and assess dilution from warrants and convertible preferred stock.
- Progress, cost, and continuity of manufacturing transfers from Baxter, including any remaining-inventory purchase obligation.
- Nasdaq stockholders’ equity compliance and any subsequent listing or financing developments.
- Reimbursement coverage, clinical evidence, and customer adoption for the specific Aquadex indications and care settings.